New U.S. China Investment Rules Likely to Spare Most Pharma Licensing Deals

New U.S. Treasury rules on outbound investment in China are expected to leave most pharmaceutical licensing deals intact, according to both Fierce Pharma and STAT. The draft rules would restrict certain types of investment, but licensing agreements—a key route for U.S. companies to obtain rights to Chinese-developed drugs—appear likely to be preserved. The two outlets agree on this point, despite reporting from different angles.

Fierce Pharma adds that data from the WCLC26 conference generated the week's other big headlines. Akeso and Summit's ivonescimab and B7-H3 antibody-drug conjugates attracted attention, while Enhertu delivered a surprise negative overall survival trend. These clinical storylines are not mentioned in STAT's newsletter, which focuses on the regulatory outlook and other pharma news.

Fierce Pharma also reports that Legend Biotech is appointing a new CEO. That leadership change is separate from the China-rules story, and STAT does not cover it. Together, the two sources offer a broad snapshot: a regulatory path that appears relatively stable for cross-border licensing, alongside ongoing clinical and corporate developments in oncology.